Janssen’s single-shot Covid-19 vaccine 85% effective
Cheap and transportable jab provides good protection against serious symptoms
A Covid vaccine developed by healthcare giant Johnson & Johnson is 85% effective at preventing the most serious coronavirus symptoms after a single dose.
The company said that latest trials - conducted in several countries - also showed that the vaccine was 66% effective at preventing moderate to severe illness.
Britain has already ordered 30 million doses of the jab, which is pending approval by the Medicines and Healthcare products Regulatory Agency.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How does the jab work?
Like the Oxford vaccine, the Janssen drug uses a modified adenovirus, a harmless, engineered virus that is injected into the patient. The adenovirus DNA triggers an immune response that helps protect the body from Covid-19 infection.
“Unlike other candidates, however, major US trials have focused on its effectiveness as a single dose,” says The Telegraph.
Those trials have found that the jab, which costs around $10 (£7.28) per dose, is highly effective (85%) at preventing the most serious symptoms associated with Covid infection, as well as being marginally less effective (66%) at preventing even the most moderate symptoms.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
There was some variation in the drugs efficacy against different strains of the virus, with it being 72% effective against moderate to severe Covid-19 in the US, compared to 57% in South Africa, which is home to a more transmissible Covid variant.
As well as being a single-shot vaccine, “it also only needs to be kept at fridge temperature, making its storage, distribution and handling much easier”, Sky News reports.
The data from the trial will be submitted to regulators, and trials will continue while further information is shared as part of a rolling review. Johnson & Johnson is also conducting a second phase-three trial to look into the effects of two doses of the vaccine.
Create an account with the same email registered to your subscription to unlock access.
Joe Evans is the world news editor at TheWeek.co.uk. He joined the team in 2019 and held roles including deputy news editor and acting news editor before moving into his current position in early 2021. He is a regular panellist on The Week Unwrapped podcast, discussing politics and foreign affairs.
Before joining The Week, he worked as a freelance journalist covering the UK and Ireland for German newspapers and magazines. A series of features on Brexit and the Irish border got him nominated for the Hostwriter Prize in 2019. Prior to settling down in London, he lived and worked in Cambodia, where he ran communications for a non-governmental organisation and worked as a journalist covering Southeast Asia. He has a master’s degree in journalism from City, University of London, and before that studied English Literature at the University of Manchester.
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published